Website Overview: adcoris.com.cn
General information
Last Updated: 2024-05-30 (yyyy-mm-dd).
Title: Hangzhou Adcoris BioPharma Co Ltd
Description: Adcoris is a clinical stage biopharmaceutical company focusing on developing the next generation antibody drug conjugate ADC and antibody conjugate beyond cytotoxic payload AXC therapeutics to address the unmet needs in oncology and autoimmune disease Our state of the art proprietary technology platform is based on internally developed three pillars of ADC technologies proprietary and highly active payloads PHAP cleavable flexible and stable linkers CLEF multifunctional site specific conjugation MuSC We can accelerate the development of ADC and AXC from target to IND enabling within 15 months We have built a robust product pipeline including first in class FIC and first in generation FIG ADC and AXC in various development stages One ADC product has finished phase 1 clinical study with excellent safety and efficacy profiles 3 FIC and 4 FIG products are in IND enabling and preclinical candidate stage Adcoris was started by a group of highly experienced experts with rich experience in ADC medicinal chemistry biotechnology pharmacology management and business development Adcoris is well positioned to play a leading role in the era of new generation antibody bioconjugate therapeutics i e ADC and AXC
Language: English
Contact information
- bd [at]adcoris.com.cn
- info [at]adcoris.com.cn
Services and technology that the website used
Vendor
- Email Vendor: mxhichina.com